The use of drugs that affect the cell cycle represents one of the common strategies for the control of some unrelated pathologies, such as chronic viral HIV infections or cancer. The authors report the case of a patient followed for a hormone receptor-positive (HR+)/HER2 negative (HER2-) advanced breast cancer, treated with hormone therapy and CDK 4/6 inhibitors, and a concomitant HIV infection under antiretroviral treatment. The authors consider the function of the sterile alpha motif and HD domain-containing protein-1 (SAMHD1) enzyme, its implications in the control of viral replication and the correlation between its activity and the mechanism of action of the CDK 4/6 inhibitor palbociclib.
Palbociclib in a patient with HR+/HER2- advanced breast cancer and HIV1 infection: A case report / Canino, F.; Moscetti, L.; Borghi, V.; Dominici, M.; Piacentini, F.. - In: BREAST CANCER MANAGEMENT. - ISSN 1758-1931. - 10:4(2021), pp. 1-6. [10.2217/bmt-2021-0006]
Palbociclib in a patient with HR+/HER2- advanced breast cancer and HIV1 infection: A case report
Dominici M.;Piacentini F.
2021
Abstract
The use of drugs that affect the cell cycle represents one of the common strategies for the control of some unrelated pathologies, such as chronic viral HIV infections or cancer. The authors report the case of a patient followed for a hormone receptor-positive (HR+)/HER2 negative (HER2-) advanced breast cancer, treated with hormone therapy and CDK 4/6 inhibitors, and a concomitant HIV infection under antiretroviral treatment. The authors consider the function of the sterile alpha motif and HD domain-containing protein-1 (SAMHD1) enzyme, its implications in the control of viral replication and the correlation between its activity and the mechanism of action of the CDK 4/6 inhibitor palbociclib.File | Dimensione | Formato | |
---|---|---|---|
Palbociclib in a patient.pdf
Open access
Tipologia:
Versione pubblicata dall'editore
Dimensione
908.18 kB
Formato
Adobe PDF
|
908.18 kB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris